COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors

28Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The study objective was to identify sociodemographic and coronavirus disease 2019 (COVID-19) factors that are associated with COVID-19 vaccine hesitancy among adolescent and young adult (AYA) cancer survivors. Eligible participants were 18 years or older and were diagnosed with cancer as an AYA (ages 15-39 years) and received services through an AYA cancer program. A total of 342 participants completed a cross-sectional survey. Our primary outcome - COVID-19 vaccine hesitancy - was surveyed as a 5-point Likert scale and operationalized as a binary outcome (agree vs hesitant). A large proportion of participants reported COVID-19 vaccine hesitancy (37.1%). In the multivariable regression, female survivors (odds ratio = 1.81, 95% confidence interval = 1.10 to 2.98) and survivors with a high school education or less (odds ratio = 3.15, 95% confidence interval = 1.41 to 7.04) reported higher odds of vaccine hesitancy compared with their male or college graduate or higher counterparts. COVID-19 vaccine hesitancy persists among AYA survivors despite their recommended priority vaccination status and higher chances of severe COVID-19 outcomes.

Cite

CITATION STYLE

APA

Waters, A. R., Kepka, D., Ramsay, J. M., Mann, K., Vaca Lopez, P. L., Anderson, J. S., … Warner, E. L. (2021). COVID-19 Vaccine Hesitancy Among Adolescent and Young Adult Cancer Survivors. JNCI Cancer Spectrum, 5(3). https://doi.org/10.1093/jncics/pkab049

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free